FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105404731> ?p ?o ?g. }

• W2105404731 endingPage "431" @default.
• W2105404731 startingPage "424" @default.
• W2105404731 abstract "Background Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter.Design and Methods Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation.Results Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis.Conclusions The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found." @default.
• W2105404731 created "2016-06-24" @default.
• W2105404731 creator A5000230349 @default.
• W2105404731 creator A5003682435 @default.
• W2105404731 creator A5005056682 @default.
• W2105404731 creator A5006173909 @default.
• W2105404731 creator A5010010012 @default.
• W2105404731 creator A5017341923 @default.
• W2105404731 creator A5022310570 @default.
• W2105404731 creator A5026592803 @default.
• W2105404731 creator A5027873095 @default.
• W2105404731 creator A5029641771 @default.
• W2105404731 creator A5030067333 @default.
• W2105404731 creator A5031467969 @default.
• W2105404731 creator A5045288476 @default.
• W2105404731 creator A5046775582 @default.
• W2105404731 creator A5050532707 @default.
• W2105404731 creator A5051138260 @default.
• W2105404731 creator A5056902311 @default.
• W2105404731 creator A5059808568 @default.
• W2105404731 creator A5076578888 @default.
• W2105404731 creator A5091271737 @default.
• W2105404731 date "2009-11-10" @default.
• W2105404731 modified "2023-10-04" @default.
• W2105404731 title "Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy" @default.
• W2105404731 cites W1492609361 @default.
• W2105404731 cites W1531493896 @default.
• W2105404731 cites W1534965621 @default.
• W2105404731 cites W1576475831 @default.
• W2105404731 cites W1964622335 @default.
• W2105404731 cites W1979300931 @default.
• W2105404731 cites W2024462993 @default.
• W2105404731 cites W2037991379 @default.
• W2105404731 cites W2042331757 @default.
• W2105404731 cites W2055722425 @default.
• W2105404731 cites W2074453573 @default.
• W2105404731 cites W2085251563 @default.
• W2105404731 cites W2109653033 @default.
• W2105404731 cites W2138630072 @default.
• W2105404731 cites W2139984188 @default.
• W2105404731 cites W2148047805 @default.
• W2105404731 cites W2159967007 @default.
• W2105404731 cites W2231014749 @default.
• W2105404731 cites W2244261822 @default.
• W2105404731 cites W2284883608 @default.
• W2105404731 cites W2330058030 @default.
• W2105404731 cites W2414626961 @default.
• W2105404731 cites W579135650 @default.
• W2105404731 cites W2147083172 @default.
• W2105404731 cites W2995133996 @default.
• W2105404731 doi "https://doi.org/10.3324/haematol.2009.013243" @default.
• W2105404731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2833072" @default.
• W2105404731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19903674" @default.
• W2105404731 hasPublicationYear "2009" @default.
• W2105404731 type Work @default.
• W2105404731 sameAs 2105404731 @default.
• W2105404731 citedByCount "71" @default.
• W2105404731 countsByYear W21054047312012 @default.
• W2105404731 countsByYear W21054047312013 @default.
• W2105404731 countsByYear W21054047312014 @default.
• W2105404731 countsByYear W21054047312015 @default.
• W2105404731 countsByYear W21054047312016 @default.
• W2105404731 countsByYear W21054047312017 @default.
• W2105404731 countsByYear W21054047312018 @default.
• W2105404731 countsByYear W21054047312019 @default.
• W2105404731 countsByYear W21054047312020 @default.
• W2105404731 countsByYear W21054047312021 @default.
• W2105404731 countsByYear W21054047312022 @default.
• W2105404731 countsByYear W21054047312023 @default.
• W2105404731 crossrefType "journal-article" @default.
• W2105404731 hasAuthorship W2105404731A5000230349 @default.
• W2105404731 hasAuthorship W2105404731A5003682435 @default.
• W2105404731 hasAuthorship W2105404731A5005056682 @default.
• W2105404731 hasAuthorship W2105404731A5006173909 @default.
• W2105404731 hasAuthorship W2105404731A5010010012 @default.
• W2105404731 hasAuthorship W2105404731A5017341923 @default.
• W2105404731 hasAuthorship W2105404731A5022310570 @default.
• W2105404731 hasAuthorship W2105404731A5026592803 @default.
• W2105404731 hasAuthorship W2105404731A5027873095 @default.
• W2105404731 hasAuthorship W2105404731A5029641771 @default.
• W2105404731 hasAuthorship W2105404731A5030067333 @default.
• W2105404731 hasAuthorship W2105404731A5031467969 @default.
• W2105404731 hasAuthorship W2105404731A5045288476 @default.
• W2105404731 hasAuthorship W2105404731A5046775582 @default.
• W2105404731 hasAuthorship W2105404731A5050532707 @default.
• W2105404731 hasAuthorship W2105404731A5051138260 @default.
• W2105404731 hasAuthorship W2105404731A5056902311 @default.
• W2105404731 hasAuthorship W2105404731A5059808568 @default.
• W2105404731 hasAuthorship W2105404731A5076578888 @default.
• W2105404731 hasAuthorship W2105404731A5091271737 @default.
• W2105404731 hasBestOaLocation W21054047311 @default.
• W2105404731 hasConcept C104317684 @default.
• W2105404731 hasConcept C126322002 @default.
• W2105404731 hasConcept C143998085 @default.
• W2105404731 hasConcept C144301174 @default.
• W2105404731 hasConcept C174475383 @default.
• W2105404731 hasConcept C203014093 @default.
• W2105404731 hasConcept C2776601000 @default.

• next